WO2010149598A3 - Compose antiviral heterocyclique - Google Patents

Compose antiviral heterocyclique Download PDF

Info

Publication number
WO2010149598A3
WO2010149598A3 PCT/EP2010/058681 EP2010058681W WO2010149598A3 WO 2010149598 A3 WO2010149598 A3 WO 2010149598A3 EP 2010058681 W EP2010058681 W EP 2010058681W WO 2010149598 A3 WO2010149598 A3 WO 2010149598A3
Authority
WO
WIPO (PCT)
Prior art keywords
antiviral compound
heterocyclic antiviral
heterocyclic
hepatitis
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/058681
Other languages
English (en)
Other versions
WO2010149598A2 (fr
Inventor
Elbert Chin
Javier De Vicente Fidalgo
Jim Li
Alfred Sui-Ting Lui
Kristen Lynn Mccaleb
Ryan Craig Schoenfeld
Francisco Xavier Talamas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI1011744A priority Critical patent/BRPI1011744A2/pt
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to AU2010264802A priority patent/AU2010264802A1/en
Priority to CN2010800278002A priority patent/CN102803212A/zh
Priority to MX2011012541A priority patent/MX2011012541A/es
Priority to SG2011095742A priority patent/SG176976A1/en
Priority to CA2762675A priority patent/CA2762675A1/fr
Priority to EP10726075A priority patent/EP2445875A2/fr
Priority to JP2012516672A priority patent/JP2012530751A/ja
Publication of WO2010149598A2 publication Critical patent/WO2010149598A2/fr
Publication of WO2010149598A3 publication Critical patent/WO2010149598A3/fr
Priority to IL216338A priority patent/IL216338A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/34—Ethylene-urea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés de formule I dans laquelle R1, R2, R3, R4, et R5 sont tels que définis dans la description qui sont des inhibiteurs de la polymérase NS5b du virus de l'hépatite C. L'invention concerne également des compositions et des procédés pour le traitement d'une infection de VCH et l'inhibition de réplication du VHC.
PCT/EP2010/058681 2009-06-24 2010-06-21 Compose antiviral heterocyclique Ceased WO2010149598A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2012516672A JP2012530751A (ja) 2009-06-24 2010-06-21 複素環式の抗ウイルス性化合物
AU2010264802A AU2010264802A1 (en) 2009-06-24 2010-06-21 Heterocyclic antiviral compound
CN2010800278002A CN102803212A (zh) 2009-06-24 2010-06-21 抗病毒的杂环化合物
MX2011012541A MX2011012541A (es) 2009-06-24 2010-06-21 Compuestos heterociclicos antivirales.
SG2011095742A SG176976A1 (en) 2009-06-24 2010-06-21 Heterocyclic antiviral compound
BRPI1011744A BRPI1011744A2 (pt) 2009-06-24 2010-06-21 composto antiviral heterocíclico.
EP10726075A EP2445875A2 (fr) 2009-06-24 2010-06-21 Compose antiviral heterocyclique
CA2762675A CA2762675A1 (fr) 2009-06-24 2010-06-21 Compose antiviral heterocyclique
IL216338A IL216338A0 (en) 2009-06-24 2011-11-14 Heterocyclic antiviral compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21997709P 2009-06-24 2009-06-24
US61/219,977 2009-06-24

Publications (2)

Publication Number Publication Date
WO2010149598A2 WO2010149598A2 (fr) 2010-12-29
WO2010149598A3 true WO2010149598A3 (fr) 2011-05-19

Family

ID=42942262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/058681 Ceased WO2010149598A2 (fr) 2009-06-24 2010-06-21 Compose antiviral heterocyclique

Country Status (13)

Country Link
US (1) US8158631B2 (fr)
EP (1) EP2445875A2 (fr)
JP (1) JP2012530751A (fr)
CN (1) CN102803212A (fr)
AR (1) AR077173A1 (fr)
AU (1) AU2010264802A1 (fr)
BR (1) BRPI1011744A2 (fr)
CA (1) CA2762675A1 (fr)
IL (1) IL216338A0 (fr)
MX (1) MX2011012541A (fr)
SG (1) SG176976A1 (fr)
TW (1) TW201103545A (fr)
WO (1) WO2010149598A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110094352A (ko) * 2008-12-22 2011-08-23 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
RU2015144653A (ru) 2009-03-25 2018-12-29 Эббви Инк. Противовирусные соединения и их применения
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US8841487B2 (en) 2010-07-16 2014-09-23 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
NZ705225A (en) 2010-07-16 2016-11-25 Abbvie Bahamas Ltd Process for preparing antiviral compounds
WO2014031791A1 (fr) * 2012-08-21 2014-02-27 Abbvie Inc. Procédé de préparation de composés antiviraux
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
KR102972576B1 (ko) * 2024-01-08 2026-06-05 대한민국 니트로벤즈알데히드계 화합물을 유효성분으로 포함하는 항-hiv-1 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005785A1 (fr) * 1999-07-14 2001-01-25 Bayer Aktiengesellschaft Phenyluraciles substitues
WO2004041799A1 (fr) * 2002-11-07 2004-05-21 Astrazeneca Ab Thiadiazolidine-3-ones 5-(phenyle substitue) et leur utilisation en tant qu'inhibiteurs de ptp1b
WO2004050619A1 (fr) * 2002-12-05 2004-06-17 Glaxo Group Limited Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
WO2009039135A1 (fr) * 2007-09-17 2009-03-26 Abbott Laboratories N-phényl-dioxo-hydropyrimidines utiles en tant qu'inhibiteurs du virus de l'hépatite c (vhc)
WO2009039127A1 (fr) * 2007-09-17 2009-03-26 Abbott Laboratories Dérivé d'uracile ou de thymine pour le traitement de l'hépatite c

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1407899A (en) * 1997-12-01 1999-06-16 E.I. Du Pont De Nemours And Company Fungicidal cyclic amides
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ATE357421T1 (de) 1999-12-24 2007-04-15 Asahi Glass Co Ltd Siliziumnitrid filter und verfahren zu dessen herstellung
WO2001085172A1 (fr) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Nouveaux anti-infectieux
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (fr) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
WO2003037262A2 (fr) 2001-10-29 2003-05-08 Smithkline Beecham Corporation Nouveaux anti-infectieux
WO2003059356A2 (fr) 2001-10-30 2003-07-24 Smithkline Beecham Corporation Nouveaux anti-infectieux
WO2003099801A1 (fr) 2002-05-24 2003-12-04 Smithkline Beecham Corporation Nouveaux anti-infectieux
BR0315897A (pt) 2002-11-01 2008-05-13 Abbott Lab agentes antiinfecciosos
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004052312A2 (fr) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Agents anti-infectieux
WO2004052313A2 (fr) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Agents antiinfectieux
WO2004058150A2 (fr) 2002-12-17 2004-07-15 Smithkline Beecham Corporation Anti-infectieux
WO2005019191A2 (fr) 2003-08-25 2005-03-03 Abbott Laboratories Agents anti-infectieux
WO2006021340A1 (fr) 2004-08-23 2006-03-02 F.Hoffmann-La Roche Ag Composés antiviraux hétérocycliques
MX2007013415A (es) 2005-05-04 2008-01-15 Hoffmann La Roche Compuestos antivirales heterociclicos.
JP5179585B2 (ja) 2007-08-29 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 四環系インドール誘導体およびその使用法
EP2195317B1 (fr) 2007-08-29 2012-01-18 Schering Corporation Dérivés d'azaindoles substitués en 2 et 3 destinés au traitement d'infections virales
RU2010111550A (ru) 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) 2,3-замещенные индольные производные для лечения вирусных инфекций
WO2009039134A1 (fr) 2007-09-17 2009-03-26 Abbott Laboratories Agents anti-infectieux et leurs utilisations
US8765757B2 (en) 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
CN102317285A (zh) 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
RU2552533C2 (ru) 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
RU2015144653A (ru) 2009-03-25 2018-12-29 Эббви Инк. Противовирусные соединения и их применения

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005785A1 (fr) * 1999-07-14 2001-01-25 Bayer Aktiengesellschaft Phenyluraciles substitues
WO2004041799A1 (fr) * 2002-11-07 2004-05-21 Astrazeneca Ab Thiadiazolidine-3-ones 5-(phenyle substitue) et leur utilisation en tant qu'inhibiteurs de ptp1b
WO2004050619A1 (fr) * 2002-12-05 2004-06-17 Glaxo Group Limited Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
WO2009039135A1 (fr) * 2007-09-17 2009-03-26 Abbott Laboratories N-phényl-dioxo-hydropyrimidines utiles en tant qu'inhibiteurs du virus de l'hépatite c (vhc)
WO2009039127A1 (fr) * 2007-09-17 2009-03-26 Abbott Laboratories Dérivé d'uracile ou de thymine pour le traitement de l'hépatite c

Also Published As

Publication number Publication date
CN102803212A (zh) 2012-11-28
WO2010149598A2 (fr) 2010-12-29
TW201103545A (en) 2011-02-01
BRPI1011744A2 (pt) 2016-03-22
IL216338A0 (en) 2012-01-31
US8158631B2 (en) 2012-04-17
AR077173A1 (es) 2011-08-10
MX2011012541A (es) 2012-08-03
US20100330032A1 (en) 2010-12-30
SG176976A1 (en) 2012-02-28
AU2010264802A1 (en) 2012-01-19
JP2012530751A (ja) 2012-12-06
EP2445875A2 (fr) 2012-05-02
CA2762675A1 (fr) 2010-12-29

Similar Documents

Publication Publication Date Title
MX2010004623A (es) Compuestos heterociclicos antiviricos.
MX2012003170A (es) Compuestos heterociclicos antivirales.
MX2012008443A (es) Nucleosidos antiviricos.
WO2009069095A3 (fr) Composés nucléosidiques antiviraux
MY157435A (en) Heterocyclic antiviral compounds
WO2008060927A3 (fr) Inhibiteurs du virus c de l'hépatite
UA91255C2 (uk) Антивірусні нуклеозиди
WO2008008776A3 (fr) Inhibiteurs du virus de l'hépatite c
IL198741A0 (en) Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
WO2007092888A3 (fr) Inhibiteurs ns5b hcv
WO2008021936A3 (fr) Inhibiteurs du virus de l'hépatite c
TW200720285A (en) Nucleoside compounds for treating viral infections
WO2006122188A3 (fr) Inhibiteurs du virus de l'hepatite c
WO2008057208A3 (fr) Inhibiteurs de protéase ns3 du vhc
WO2008051514A3 (fr) Inhibiteurs de la protéase ns3 du hcv
WO2008051475A3 (fr) Inhibiteurs de la protéase ns3 du vhc
WO2008021927A3 (fr) Inhibiteurs du virus de l'hépatite c
WO2011106992A8 (fr) Inhibiteurs de polymérase du virus de l'hépatite c ns5b
WO2007140200A3 (fr) Inhibiteurs de la ns5b du vch à base d'indolobenzazépine fusionnée au cyclopropyle
WO2007140254A3 (fr) Inhibiteurs de ns5b de vhc de type indolobenzapénine fusionnée cyclopropyle
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
TW200724540A (en) Heterocyclic antiviral compounds
MX2011012541A (es) Compuestos heterociclicos antivirales.
WO2012019299A9 (fr) Composés inhibiteurs de l'hépatite c

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080027800.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10726075

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2010726075

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010726075

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2762675

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/012541

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010264802

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2012516672

Country of ref document: JP

Ref document number: 9686/CHENP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010264802

Country of ref document: AU

Date of ref document: 20100621

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020127001697

Country of ref document: KR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1011744

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1011744

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111223